BR112023002608A2 - Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade - Google Patents
Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedadeInfo
- Publication number
- BR112023002608A2 BR112023002608A2 BR112023002608A BR112023002608A BR112023002608A2 BR 112023002608 A2 BR112023002608 A2 BR 112023002608A2 BR 112023002608 A BR112023002608 A BR 112023002608A BR 112023002608 A BR112023002608 A BR 112023002608A BR 112023002608 A2 BR112023002608 A2 BR 112023002608A2
- Authority
- BR
- Brazil
- Prior art keywords
- exendin
- satiity
- obesity
- enhancement
- treatment
- Prior art date
Links
- 108010011459 Exenatide Proteins 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA202070526 | 2020-08-12 | ||
| PCT/EP2021/072251 WO2022034062A1 (en) | 2020-08-12 | 2021-08-10 | Exendin-4 peptide analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002608A2 true BR112023002608A2 (pt) | 2023-05-09 |
Family
ID=80246995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002608A BR112023002608A2 (pt) | 2020-08-12 | 2021-08-10 | Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230303640A1 (https=) |
| EP (1) | EP4196495A1 (https=) |
| JP (1) | JP2023538871A (https=) |
| CN (1) | CN116390938A (https=) |
| AU (1) | AU2021324066A1 (https=) |
| BR (1) | BR112023002608A2 (https=) |
| CA (1) | CA3190959A1 (https=) |
| WO (1) | WO2022034062A1 (https=) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| EP1525219B1 (en) * | 2002-07-04 | 2009-05-27 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
| EP1919947B1 (en) | 2005-08-26 | 2013-02-27 | AbbVie Inc. | Therapeutically active alpha-msh analogues |
| JP5241849B2 (ja) * | 2007-11-16 | 2013-07-17 | ノボ・ノルデイスク・エー／エス | インスリン及びインスリン分泌性ペプチドを含む薬学的組成物 |
| JP2014521594A (ja) * | 2011-05-25 | 2014-08-28 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 長持続期間デュアルホルモンコンジュゲート |
| US9217023B2 (en) | 2012-10-19 | 2015-12-22 | Txp Pharma Gmbh | Alpha- and gamma-MSH analogues |
| HK1211232A1 (en) * | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| EP3838285A1 (en) | 2014-04-22 | 2021-06-23 | TXP Pharma GmbH | Peptide analogues with branched amino acid probe(s) |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
-
2021
- 2021-08-10 WO PCT/EP2021/072251 patent/WO2022034062A1/en not_active Ceased
- 2021-08-10 AU AU2021324066A patent/AU2021324066A1/en active Pending
- 2021-08-10 EP EP21766122.2A patent/EP4196495A1/en active Pending
- 2021-08-10 CA CA3190959A patent/CA3190959A1/en active Pending
- 2021-08-10 US US18/020,813 patent/US20230303640A1/en active Pending
- 2021-08-10 JP JP2023510345A patent/JP2023538871A/ja active Pending
- 2021-08-10 BR BR112023002608A patent/BR112023002608A2/pt unknown
- 2021-08-10 CN CN202180069840.1A patent/CN116390938A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3190959A1 (en) | 2022-02-17 |
| AU2021324066A1 (en) | 2023-03-30 |
| WO2022034062A1 (en) | 2022-02-17 |
| US20230303640A1 (en) | 2023-09-28 |
| JP2023538871A (ja) | 2023-09-12 |
| EP4196495A1 (en) | 2023-06-21 |
| CN116390938A (zh) | 2023-07-04 |
| AU2021324066A9 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017430A2 (pt) | Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos | |
| BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
| AR111122A1 (es) | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro | |
| Guo et al. | Hydrogen sulfide as an endogenous modulator in mitochondria and mitochondria dysfunction | |
| BR112021021318A2 (pt) | Sapato funcional fácil de usar | |
| BR112021015832A2 (pt) | Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos | |
| NO20092774L (no) | HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| BR112021022527A2 (pt) | Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos | |
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| BR112019009133A2 (pt) | vacina contra o parvovírus suíno | |
| BRPI0717098B8 (pt) | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação | |
| BR112016029713A2 (pt) | métodos para o tratamento de sobrepeso ou obesidade | |
| BR112018075396A2 (pt) | anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika | |
| BR112022005757A2 (pt) | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma | |
| MY206268A (en) | Modified s1 subunit of the coronavirus spike protein | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| EA200900373A1 (ru) | Реконструированные сурфактанты, обладающие улучшенными свойствами | |
| BR112022024662A2 (pt) | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 | |
| BR112022014844A2 (pt) | Tratamento de doenças associadas ao panx1 | |
| BRPI0515857A (pt) | conjugados do fator-i de crescimento semelhante à insulina ( igf-i ) e polietileno glicol | |
| EA201990479A1 (ru) | Сульфонамиды в качестве агонистов gpr40 и gpr120 | |
| BR112021023957A2 (pt) | Peptídeos | |
| BR112023002608A2 (pt) | Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade | |
| BR112018068414A2 (pt) | derivados de ácido a-truxílico e composições farmacêuticas dos mesmos |